IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy

This study has been completed.

First Received on February 11, 2008. Last Updated on November 19, 2008 History of Changes

Sponsor:	University of Zurich
Collaborator:	ImVision AG
Information provided by:	University of Zurich
ClinicalTrials.gov Identifier:	NCT00620880

Purpose

Primary objective of the trial:

To determine at which concentration the fusion protein MAT Fel d1 degranulates basophils of cat dander allergic patients, in comparison to a cat dander extract and to Fel d1 alone

Condition	Intervention
Allergy to Cats	Behavioral: Blood sample

Study Type:	Observational
Study Design:	Time Perspective: Prospective
Official Title:	Performance of CAST With Different Allergens in Patients With Cat Dander Allergy

Resource links provided by NLM:

MedlinePlus related topics: Allergy

U.S. FDA Resources

Further study details as provided by University of Zurich:

Study Start Date:	September 2005
Study Completion Date:	September 2006

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria: 1. Patient with Cat Dander Allergy evidenced by positive history 2. Age: 18 to 75 years

Exclusion criteria: 1. Use of oral corticosteroids, Chromoglycin, Ketotifen, or any immunosuppressive drugs within the last 2 months 2. Psychiatric disorder resulting in malcompliance 3. Neg. IgE to Cat dander

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00620880

Locations

Switzerland

Zurich, Switzerland

Sponsors and Collaborators

University of Zurich

ImVision AG

Investigators

Study Director:

01 Studienregister MasterAdmins

UniversitaetsSpital Zuerich

More Information

No publications provided

Responsible Party:	University Hospital Zürich, University of Zurich
ClinicalTrials.gov Identifier:	NCT00620880 History of Changes
Other Study ID Numbers:	IVN-CAT-001A
Study First Received:	February 11, 2008
Last Updated:	November 19, 2008
Health Authority:	Switzerland: Swissmedic

Additional relevant MeSH terms:

Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on February 12, 2012